⚠ Public Cyclotrons Need No ProfitLow threat

Synektik (SNT) — threat to the moat

Four of Poland's nine cyclotrons belong to public bodies that need earn nothing on them.

Synektik's radiopharmaceutical rivals include the state. Four of Poland's nine cyclotrons were purchased and installed by public entities1, and a public producer's price does not have to earn a return on its capital.

Radiopharmaceutical sales by type, FY2025 (zł m)25,8Basic14,8Complementaryabout 10,0SpecialSynektik annual management board report, year to September 2025
The commodity tracer is half the segment.

That matters most for the basic glucose tracer, the product every PET centre uses and any licensed producer can make. Basic radiopharmaceuticals were 25,8 million złoty of Synektik's sales in the year to September 20252, about half the segment. Special products are where Synektik can differentiate, and they were nearly 10,0 million złoty3.

A new public cyclotron near one of Synektik's plants would take customers on price. Nothing in the filings suggests one is planned.

The country's cyclotrons sit in Warsaw, Kraków, Gliwice, Bydgoszcz, Kielce, Mszczonów, Łódź and Ożarów Mazowiecki4, which is to say most large Polish cities already have a producer within delivery range. The space for a new entrant, public or private, is limited, and so is the space for Synektik to open new plants.

A sustained fall in basic radiopharmaceutical revenue, 7,2 million złoty in the April-June 2026 quarter5, would show competition reaching the core product.

References
  1. ReportedFour of Poland's nine cyclotrons were purchased and installed by public entities, and a public producer's price does not have to earn a return on its capital.
    Synektik annual management board report for the fiscal year to 30 September 2025 - risk factors, customers and suppliers (Intuitive's share of revenue and purchases, public procurement, Affidea, seasonality). — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedBasic radiopharmaceuticals were 25,8 million złoty of Synektik's sales in the year to September 2025, about half the segment.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  3. ReportedSpecial products are where Synektik can differentiate, and they were nearly 10,0 million złoty.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  4. ReportedThe country's cyclotrons sit in Warsaw, Kraków, Gliwice, Bydgoszcz, Kielce, Mszczonów, Łódź and Ożarów Mazowiecki, which is to say most large Polish cities already have a producer within delivery range.
    Synektik annual management board report for the fiscal year to 30 September 2025 - description of the markets: robotic surgery in Poland, PET scanners, cyclotrons and NFZ-funded PET studies. — October 2024 - September 2025 · publ. December 2025 · source ↗
  5. ReportedA sustained fall in basic radiopharmaceutical revenue, 7,2 million złoty in the April-June 2026 quarter, would show competition reaching the core product.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - radiopharmaceutical segment: plants, products, sales by type and quarterly results. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
Sources
Generated September 24, 2026